September 18, 2013 8:55 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating on
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
(NASDAQ: RPRX), and raised the price target from $25.00 to $35.00.In the report, Bank of America noted, “Following positive top line phase 3 data (study ‘302) for RPRX's Androxal, we raised our estimated probability of approval to 90% (from 75%), lowered our assumed discount rate to 10% (from 11%) and now model faster uptake. The efficacy results from the ‘302 and previously released ‘301 trial along with six month safety data from the ‘300 trial in our view strengthens the case to approve Androxal for low testosterone (low T) treatment. RPRX remains on-track to file for US approval in mid-2014. We now model risk-adjusted sales of $450mn in 2020 ($379mn prev.). Our peak 10% market penetration forecast for Androxal is unchanged and we note this assumption could be conservative (see page 2 for sensitivity analysis on market penetration rates). Our changes resulted in an increase of $10 to our DCF-derived PO. Our new PO is $35.”Repros Therapeutics closed on Tuesday at $23.85.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.